Ensoma Focuses on Key Gene Therapy
Ensoma reduces staff and halts some research to prioritize its main gene therapy for a rare immune disease.
Biotech company Ensoma makes big changes. The company cut more jobs. This follows earlier staff reductions last November. Ensoma now has fewer employees.
Ensoma will stop some early-stage research. These programs were in preclinical testing. The company wants to save money and resources. It will put these savings toward its main drug.
Ensoma's main drug is a gene therapy. It treats a rare immune disease. The company believes this drug has great promise. This move shows Ensoma's strong commitment to one project.
This decision helps Ensoma focus. It puts all efforts on its best chance for success. This could speed up the new gene therapy. Patients waiting for new treatments may benefit.
Source: FierceBiotech
More from Biotech
